

SUNSI Review Complete
 Template = ADM-013
 E-RIDS=ADM-03
 ADD=Sarah Lopas

As of: 1/15/19 10:24 AM Received: January 12, 2019 Status: Pending_Post Tracking No. 1k3-97nc-327j Comments Due: January 29, 2019 Submission Type: Web

PUBLIC SUBMISSION

COMMENT (30)
 PUBLICATION DATE:
 10/29/2018
 CITATION: 83 FR 54380

Docket: NRC-2018-0230

Training and Experience Requirements for Different Categories of Radiopharmaceuticals

Comment On: NRC-2018-0230-0001

Training and Experience Requirements for Different Categories of Radiopharmaceuticals

Document: NRC-2018-0230-DRAFT-0028

Comment on FR Doc # 2018-23521

Submitter Information

Name: PAUL SIEBER

Address:

2106 Harrisburg Pike
 Lancaster, PA, 17604

Email: psieber610@gmail.com

General Comment

The role of the urologist in the treatment of metastatic prostate cancer continues to evolve. The use of Radium 223 is one of many agents being used routinely. Its unique properties enable easy administration in the office setting. Its toxicity is the attraction to it being a routine addition to the layering of agents in this disease. I concur, some training is required to understand its administration but it would not appear to require nuclear medicine residency to master. To the contrary it is a challenge for the nuclear medicine specialist to master the evolving space known as metastatic castration-resistant prostate cancer. In my location, the medication has been supervised by a radiation oncologist. I as the urologist identify the timing of the drug and my radiation oncologist generally just supervises the treatment. I would hope the licensing for administration can be liberalized to include interested urologists.